Initial tests showed it was up to code, but investigators later found seven failed safety standards, which officials said suggested contractors skimped to make greater profits.
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation
...
Read moreDetails
